Tarsus Pharmaceuticals (TARS) Share-based Compensation (2020 - 2026)

Tarsus Pharmaceuticals' Share-based Compensation history runs 7 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 72.68% year-over-year to $12.0 million in Q1 2026; TTM through Mar 2026 was $15.2 million, a 55.63% decrease from a year earlier, with the FY2025 full-year figure at $10.2 million, down 63.3% from the prior year.
• Share-based Compensation climbed to $12.0 million in Q1 2026 per TARS's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $20.0 million in Q3 2024 and bottomed at -$12.5 million in Q4 2023.
• The 5-year median for Share-based Compensation is $3.7 million (2022), against an average of $4.4 million.
• Across the five-year window, Share-based Compensation soared 4677.33% in 2022 and sank 440.56% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $3.7 million in 2022, then sank by 440.56% to -$12.5 million in 2023, then jumped by 159.21% to $7.4 million in 2024, then tumbled by 166.92% to -$5.0 million in 2025, then surged by 341.56% to $12.0 million in 2026.
• Per Business Quant, the three latest TARS Share-based Compensation figures stand at $12.0 million (Q1 2026), -$5.0 million (Q3 2025), and $8.2 million (Q2 2025).